Cara Therapeutics Inc (NASDAQ:CARA) – Investment analysts at Piper Jaffray Companies increased their Q3 2019 earnings estimates for Cara Therapeutics in a report issued on Tuesday, July 30th. Piper Jaffray Companies analyst D. Amsellem now expects that the biopharmaceutical company will earn ($0.62) per share for the quarter, up from their prior estimate of ($0.64). Piper Jaffray Companies currently has a “Overweight” rating and a $39.00 price target on the stock. Piper Jaffray Companies also issued estimates for Cara Therapeutics’ Q4 2019 earnings at ($0.63) EPS, FY2019 earnings at ($2.39) EPS, Q1 2020 earnings at ($0.66) EPS, Q2 2020 earnings at ($0.67) EPS, Q3 2020 earnings at ($0.60) EPS, FY2020 earnings at ($2.48) EPS, FY2021 earnings at ($2.07) EPS and FY2022 earnings at $0.25 EPS.
A number of other brokerages have also recently commented on CARA. Zacks Investment Research cut shares of Cara Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday. BidaskClub cut shares of Cara Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Tuesday. Laidlaw upped their price target on shares of Cara Therapeutics from $26.00 to $32.00 and gave the company a “buy” rating in a research report on Wednesday, May 29th. HC Wainwright upped their price target on shares of Cara Therapeutics from $28.00 to $31.00 and gave the company an “average” rating in a research report on Monday, July 22nd. Finally, Needham & Company LLC upped their price target on shares of Cara Therapeutics from $28.00 to $35.00 and gave the company a “buy” rating in a research report on Wednesday, May 29th. Three investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Cara Therapeutics currently has a consensus rating of “Buy” and an average target price of $26.67.
NASDAQ CARA opened at $23.94 on Thursday. The firm has a market capitalization of $909.52 million, a P/E ratio of -11.62 and a beta of 2.25. Cara Therapeutics has a twelve month low of $12.19 and a twelve month high of $27.55. The firm has a fifty day moving average of $22.39. The company has a quick ratio of 3.40, a current ratio of 3.40 and a debt-to-equity ratio of 0.04.
Cara Therapeutics (NASDAQ:CARA) last posted its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.55) by ($0.01). The company had revenue of $4.38 million during the quarter, compared to analyst estimates of $5.14 million. Cara Therapeutics had a negative net margin of 443.71% and a negative return on equity of 67.30%.
Hedge funds have recently added to or reduced their stakes in the company. TCG Advisors LP bought a new position in shares of Cara Therapeutics during the 1st quarter worth about $30,000. Aperio Group LLC acquired a new stake in shares of Cara Therapeutics in the 2nd quarter worth about $88,000. BNP Paribas Arbitrage SA raised its holdings in shares of Cara Therapeutics by 67,680.0% in the 1st quarter. BNP Paribas Arbitrage SA now owns 6,778 shares of the biopharmaceutical company’s stock worth $133,000 after acquiring an additional 6,768 shares during the last quarter. Knott David M acquired a new stake in shares of Cara Therapeutics in the 1st quarter worth about $140,000. Finally, Advisory Services Network LLC raised its holdings in shares of Cara Therapeutics by 39,086.4% in the 4th quarter. Advisory Services Network LLC now owns 8,621 shares of the biopharmaceutical company’s stock worth $112,000 after acquiring an additional 8,599 shares during the last quarter. 56.17% of the stock is currently owned by institutional investors.
In other news, CFO Mani Mohindru sold 2,496 shares of the stock in a transaction dated Wednesday, May 29th. The shares were sold at an average price of $21.39, for a total transaction of $53,389.44. Following the transaction, the chief financial officer now owns 16,359 shares of the company’s stock, valued at approximately $349,919.01. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Frederique Ph.D. Menzaghi sold 11,397 shares of the stock in a transaction dated Wednesday, May 29th. The stock was sold at an average price of $21.19, for a total transaction of $241,502.43. Following the transaction, the insider now directly owns 160,279 shares in the company, valued at approximately $3,396,312.01. The disclosure for this sale can be found here. Insiders have sold a total of 88,348 shares of company stock worth $2,088,842 in the last three months. Insiders own 5.80% of the company’s stock.
Cara Therapeutics Company Profile
Cara Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells.